Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo—but only after the company removed data from four “extreme” responders from its analysis. Investors were unconvinced by the modified results, however, sending the biotech’s shares down nearly 50% on Monday morning.

READ FULL ARTICLE Curated publisher From FierceBiotech